Enlivex up on interim Allocetra data in mid-stage COVID-19 study

 

• Enlivex Therapeutics (NASDAQ:ENLV) jumps 35% in premarket, in reaction to announcement of interim data from Phase 2 trial evaluating Allocetra in severe/critical COVID-19 patients. Interim results relate to eight patients, six of whom were in severe condition and two of whom were in critical condition.
• Data showed that 7 patients treated through November 26 had complete recovery from their respective severe/critical condition and were discharged from the hospital, after an average of 4.7 days following Allocetra administration.
• The eighth enrolled after 27 Nov. experienced a clinical improvement following Allocetra treatment, but remained hospitalized six days after treatment.
• Taken together with previously-treated patients in Phase Ib study, all 12 patients through November 26 had complete recovery and were discharged, after an average of 5.5 days following Allocetra administration.
• Overall Allocetra was well tolerated with no treatment-related serious adverse events.
• https://seekingalpha.com/news/3641329-enlivex-therapeutics-rises-on-interim-allocetra-data-in-mid-stage-covidminus-19-study